Rewriting Life

Blood Feud

In biotech, one drug can make a company. For Amgen of Thousand Oaks, Calif., the nation’s largest biotech firm, that drug is the anemia treatment erythropoietin (EPO). The best-selling protein racked up $2 billion in revenues for Amgen in 1999 and is paying for the 87,000-square-meter (285,000-square-foot), state-of-the-art laboratory the company is building in the heart of Cambridge, Mass.

But just a few blocks away, at Transkaryotic Therapies (TKT), some clever Cambridge competitors are set to challenge Amgen’s pre-eminence with a version of EPO they believe gets around Amgen’s suite of patents. If successful, TKT’s “end-around” could lead to additional knockoffs of some of the world’s largest-selling biotech pharmaceuticals.

In the early 1980s, Amgen was first to discover and patent the gene that encodes the EPO protein. To manufacture EPO, Amgen adds a copy of the gene to rodent cells growing in culture. TKT’s strategy calls for using human cells instead; latent copies of the EPO gene are turned on in human cells grown in the lab, bypassing Amgen’s patents on the gene and its production method.

This story is part of our March/April 2000 Issue
See the rest of the issue
Subscribe

Amgen originally hauled TKT into court in 1997. But TKT sidestepped the legal challenge thanks to a loophole that immunizes companies from patent infringement suits while testing a drug. Now that TKT and its partner, the French-based drug firm Aventis, have finished studies in patients and are preparing to seek FDA approval to market its version of EPO, the parties are set to meet Amgen in a Boston courtroom this April.

Robert Frank, an attorney with Boston’s Choate, Hall & Stewart who represents TKT, says the case will be significant not only because of the money at stake, but also because it will test just how well-defended the patents that undergird biotech’s pioneering companies really are. TKT is betting that it’s found a chink in their armor. After EPO, TKT has secrecy-shrouded plans to take on six more of the top drugs in the worldwide $15 billion protein-therapy market.

Tech Obsessive?
Become an Insider to get the story behind the story — and before anyone else.
Subscribe today

Uh oh–you've read all five of your free articles for this month.

Insider Premium

$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.

  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus ad-free web experience, select discounts to partner offerings and MIT Technology Review events

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

    Access to the Magazine archive. Over 24,000 articles going back to 1899 at your fingertips.

    Special Discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

You've read of free articles this month.